201 related articles for article (PubMed ID: 25003660)
1. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
Znojek P; Willmore E; Curtin NJ
Br J Cancer; 2014 Sep; 111(7):1319-26. PubMed ID: 25003660
[TBL] [Abstract][Full Text] [Related]
2. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
3. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
4. Deoxyguanosine enhances the cytotoxicity of the topoisomerase I inhibitor camptothecin by reducing the repair of double-strand breaks induced in replicating DNA.
Squires S; Ryan AJ; Strutt HL; Smith PJ; Johnson RT
J Cell Sci; 1991 Dec; 100 ( Pt 4)():883-93. PubMed ID: 1726104
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase I poisoning results in PARP-mediated replication fork reversal.
Ray Chaudhuri A; Hashimoto Y; Herrador R; Neelsen KJ; Fachinetti D; Bermejo R; Cocito A; Costanzo V; Lopes M
Nat Struct Mol Biol; 2012 Mar; 19(4):417-23. PubMed ID: 22388737
[TBL] [Abstract][Full Text] [Related]
6. Mycoplasma fermentans inhibits the activity of cellular DNA topoisomerase I by activation of PARP1 and alters the efficacy of its anti-cancer inhibitor.
Afriat R; Horowitz S; Priel E
PLoS One; 2013; 8(8):e72377. PubMed ID: 24013388
[TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
[TBL] [Abstract][Full Text] [Related]
9. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition.
Berti M; Ray Chaudhuri A; Thangavel S; Gomathinayagam S; Kenig S; Vujanovic M; Odreman F; Glatter T; Graziano S; Mendoza-Maldonado R; Marino F; Lucic B; Biasin V; Gstaiger M; Aebersold R; Sidorova JM; Monnat RJ; Lopes M; Vindigni A
Nat Struct Mol Biol; 2013 Mar; 20(3):347-54. PubMed ID: 23396353
[TBL] [Abstract][Full Text] [Related]
10. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
11. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
12. PARP and CSB modulate the processing of transcription-mediated DNA strand breaks.
Sakai A; Sakasai R; Kakeji Y; Kitao H; Maehara Y
Genes Genet Syst; 2012; 87(4):265-72. PubMed ID: 23229313
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.
Park SY; Cheng YC
Cancer Res; 2005 May; 65(9):3894-902. PubMed ID: 15867389
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
15. PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA.
Loseva O; Jemth AS; Bryant HE; Schüler H; Lehtiö L; Karlberg T; Helleday T
J Biol Chem; 2010 Mar; 285(11):8054-60. PubMed ID: 20064938
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
17. Cleavage of Poly(ADP-ribose) polymerase measured in situ in individual cells: relationship to DNA fragmentation and cell cycle position during apoptosis.
Li X; Darzynkiewicz Z
Exp Cell Res; 2000 Feb; 255(1):125-32. PubMed ID: 10666341
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
19. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
20. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
